Mitsubishi Pharma Corporation

Keio University

Japan As Represented by Director General of Agency of National Institute of Infectious Diseases

Seima Itami

Kazumasa Fukuda

Tatsuo Miyamura

Yoshiharu Matsuura

Makoto Seki

Masahiko Aoki

Koichiro Kumai

Tatsurou Shibui

Yoko Hirakawa

Yoshihisa Yotsumoto

Hiroe Umeki

Saiko Hosokawa

Yoshiro Saikawa

A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.

Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent

The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.

Remedies for hepatitis C

Growing community of inventors

Tokyo, Japan

Seima Itami